[go: up one dir, main page]

SE0301109D0 - Nucleotide vaccine composition - Google Patents

Nucleotide vaccine composition

Info

Publication number
SE0301109D0
SE0301109D0 SE0301109A SE0301109A SE0301109D0 SE 0301109 D0 SE0301109 D0 SE 0301109D0 SE 0301109 A SE0301109 A SE 0301109A SE 0301109 A SE0301109 A SE 0301109A SE 0301109 D0 SE0301109 D0 SE 0301109D0
Authority
SE
Sweden
Prior art keywords
component
dendritic cells
bcr
positive tumor
plasmacytoid dendritic
Prior art date
Application number
SE0301109A
Other languages
English (en)
Inventor
Mallen Huang
Original Assignee
Mallen Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallen Huang filed Critical Mallen Huang
Priority to SE0301109A priority Critical patent/SE0301109D0/sv
Publication of SE0301109D0 publication Critical patent/SE0301109D0/sv
Priority to JP2006508023A priority patent/JP2006523688A/ja
Priority to PCT/SE2004/000589 priority patent/WO2004089413A1/en
Priority to CA002522456A priority patent/CA2522456A1/en
Priority to EP04727465A priority patent/EP1658097B1/en
Priority to AU2004227821A priority patent/AU2004227821A1/en
Priority to CN2004800164612A priority patent/CN1805758B/zh
Priority to US10/551,804 priority patent/US10799553B2/en
Priority to AT04727465T priority patent/ATE514433T1/de
Priority to US16/985,393 priority patent/US11298398B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0301109A 2003-04-14 2003-04-14 Nucleotide vaccine composition SE0301109D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition
JP2006508023A JP2006523688A (ja) 2003-04-14 2004-04-14 ヌクレオチド・ワクチン組成、ヌクレオチド及び細胞ワクチン組成の産出方法、ワクチン組成、ワクチン組成使用、免疫反応産出方法、疾患の治療または予防方法、抗原提示細胞から成るキット
PCT/SE2004/000589 WO2004089413A1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
CA002522456A CA2522456A1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
EP04727465A EP1658097B1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
AU2004227821A AU2004227821A1 (en) 2003-04-14 2004-04-14 Nucleotide vaccine composition
CN2004800164612A CN1805758B (zh) 2003-04-14 2004-04-14 核酸和细胞疫苗的组分
US10/551,804 US10799553B2 (en) 2003-04-14 2004-04-14 Composition comprising a nucleotide sequence encoding an ELA2 fusion protein and plasmacytoid dendritic cells
AT04727465T ATE514433T1 (de) 2003-04-14 2004-04-14 Nucleotid und zelluläre vakzine-zusammensetzung
US16/985,393 US11298398B2 (en) 2003-04-14 2020-08-05 Method of treating a philadelphia chromosome-positive tumor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition

Publications (1)

Publication Number Publication Date
SE0301109D0 true SE0301109D0 (sv) 2003-04-14

Family

ID=20291035

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition

Country Status (9)

Country Link
US (2) US10799553B2 (sv)
EP (1) EP1658097B1 (sv)
JP (1) JP2006523688A (sv)
CN (1) CN1805758B (sv)
AT (1) ATE514433T1 (sv)
AU (1) AU2004227821A1 (sv)
CA (1) CA2522456A1 (sv)
SE (1) SE0301109D0 (sv)
WO (1) WO2004089413A1 (sv)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
ATE534415T1 (de) 2005-12-13 2011-12-15 Harvard College Gerüste zur zelltransplantation
JPWO2008065752A1 (ja) * 2006-11-30 2010-03-04 国立大学法人北海道大学 ｄｉＲＮＡを有効成分とする免疫治療用薬剤
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CN101754776B (zh) 2007-06-19 2014-03-26 科洛普拉斯特公司 多层粘合剂器具
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
WO2009102465A2 (en) 2008-02-13 2009-08-20 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009129227A1 (en) * 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
US20100330117A1 (en) * 2008-09-26 2010-12-30 Salubrious Pharmaceutical, Llc Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
US20110020392A1 (en) * 2008-10-14 2011-01-27 Salubrious Pharmaceutical, Llc Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
CA2768552A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US9610328B2 (en) 2010-03-05 2017-04-04 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
PT2624873T (pt) 2010-10-06 2020-03-04 Harvard College Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CA2838125A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
CA2861107A1 (en) * 2012-01-13 2013-07-18 President And Fellows Of Harvard College Controlled delivery of tlr agonists in structural polymeric devices
CA2870309C (en) 2012-04-16 2024-02-20 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
KR20150058139A (ko) 2012-06-15 2015-05-28 피디에스 바이오테크놀러지 코퍼레이션 양이온성 지질 백신 조성물 및 이용 방법
EP4091630A1 (en) 2012-09-21 2022-11-23 PDS Biotechnology Corporation Vaccines comprising r-dotap
DK2958937T3 (en) * 2013-02-22 2018-11-26 Regeneron Pharma Mice expressing humanized major histocompatibility complex
CA2902543A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
CA3012602A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3280464A4 (en) 2015-04-10 2018-09-26 President and Fellows of Harvard College Immune cell trapping devices and methods for making and using the same
EP4092112A1 (en) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
MA45738A (fr) 2016-07-13 2019-05-22 Harvard College Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser
WO2018071959A1 (en) * 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles
CN107375950B (zh) * 2017-08-02 2020-10-09 深圳大学 一种重组Gal-1过敏环境免疫耐受诱导模型及建立方法
US12239666B2 (en) 2018-06-19 2025-03-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
US11413338B2 (en) 2018-07-15 2022-08-16 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
CN112048007B (zh) * 2020-09-11 2022-07-12 北京美康基免生物科技有限公司 一种通用型新型冠状病毒疫苗及其制备方法
GB202014920D0 (en) * 2020-09-22 2020-11-04 Unikum Therapeutics Aps Methods for treating cancer and autoimmune and inflammatory diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000255A1 (en) 1994-06-23 1996-01-04 Raymond Enterprises, Inc. Making lenticular optical systems and apparatus therefor
PT772619E (pt) * 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
CN1330557A (zh) * 1998-09-15 2002-01-09 匹兹堡大学联邦系统高等教育 原位注射具有基因上增进细胞因子表达的抗原呈递细胞
IL141868A0 (en) * 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
US6338040B1 (en) * 1999-02-12 2002-01-08 Agren, Inc. Method for delaying the development in pest species of resistance to control techniques, using insurance to encourage correct uses of refuges
EP1165144A2 (en) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
CA2309313A1 (en) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
US6780405B1 (en) 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
US7385023B1 (en) * 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
AU2001297693A1 (en) * 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US20060079493A1 (en) * 2001-03-01 2006-04-13 Lawrence Fritz Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors
AU2003223344B9 (en) 2002-03-22 2009-07-16 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of using in inflammation
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP1641927B1 (en) * 2003-02-18 2015-07-08 Baylor College of Medicine Induced activation in dendritic cells
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
GB2402675B (en) * 2003-05-12 2008-02-20 Oxitec Ltd Resistance dilution

Also Published As

Publication number Publication date
WO2004089413A1 (en) 2004-10-21
US11298398B2 (en) 2022-04-12
CN1805758A (zh) 2006-07-19
AU2004227821A1 (en) 2004-10-21
EP1658097B1 (en) 2011-06-29
CA2522456A1 (en) 2004-10-21
US10799553B2 (en) 2020-10-13
JP2006523688A (ja) 2006-10-19
CN1805758B (zh) 2012-04-25
US20070071722A1 (en) 2007-03-29
US20210077565A1 (en) 2021-03-18
EP1658097A1 (en) 2006-05-24
ATE514433T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
SE0301109D0 (sv) Nucleotide vaccine composition
Weissman mRNA transcript therapy
ATE412761T1 (de) Methode um rekombinante proteine in cho zellen zu exprimieren
AU4981101A (en) Subtilisin variants
PE20090731A1 (es) Metodos de produccion de proteinas basados en medios de cultivos celulares que comprenden compuestos anti-senescencia
LU91680I2 (fr) "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"
RS52790B (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
DK1409506T3 (da) Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
WO2002031134A3 (en) Novel serine protease genes related to dppiv
DK0981630T3 (da) Polypeptider med prolyldipeptidylaminopeptidaseaktivitet og nukleinsyrer, der koder for samme
WO2006130525A3 (en) Methods for immunotherapy of cancer
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
WO2006096989A3 (en) Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
ATE304603T1 (de) Induzierendes alphavirengen- expressionssystem
DE69834565D1 (de) Schnell erzeugung von stabilen säugertier-zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
ATE527349T1 (de) Nervenregeneration
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
WO2004085466A3 (en) Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use